Medical Cost-Containment Policies and Revisions to the Official Drug Price Standard
First written in FY2016. 14 of 32 entries say "Materialised", first in FY2018-Q1. Latest entry: 2026-08-06.
Vital Ksk Holdings moved to the "Worse" side of this theme in 2017, 3 years before the typical company in this theme (2020).
The whole theme swung hardest in 2020: 26 of 59 companies on the "Worse" side.
17 other companies' latest entry also says "Materialised".
- 2026-08-06MaterialisedEarnings
「In the pharmaceutical wholesale industry, the Group's principal business, drug prices were reduced following the drug price revision in April 2026. However, discussions toward fundamental reforms to policies and systems affecting people's lives and health, including the social security and drug pricing systems, are expected to intensify, and policies to control pharmaceutical costs are expected to continue.」
Reconfirms that the drug price reduction implemented in April 2026 has taken effect and that policies to control pharmaceutical costs are expected to continue. - FY2026MaterialisedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, drug prices were reduced in the April 2025 drug price revision. Discussions toward fundamental reform of policies and systems related to people's lives and health, including social security and drug pricing, are expected to intensify, and policies to contain pharmaceutical spending are expected to continue.」
It states that the April 2025 reduction in drug prices has been implemented and reconfirms the outlook for continued policies to contain pharmaceutical spending. - FY2026-H1MaterialisedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, drug prices were reduced in the April 2025 drug price revision. Discussions toward fundamental reform of policies and systems related to people's lives and health, including social security and drug pricing, are expected to intensify, and policies to contain pharmaceutical spending are expected to continue.」
It states that the reduction in drug prices under the April 2025 revision has been implemented and reconfirms the outlook for continued policies to contain pharmaceutical spending. - FY2025-H1MaterialisedAnnual report
「The healthcare cost savings from the April 2024 drug price revision amounted to approximately ¥120 billion. Discussions toward fundamental reform of policies and systems related to people's lives and health, including social security and drug pricing, are expected to intensify, and policies to contain pharmaceutical spending are expected to continue.」
It states that the healthcare cost savings from the April 2024 drug price revision actually amounted to approximately ¥120 billion. It also reconfirms the outlook for continued policies to contain pharmaceutical spending. - FY2024WorsenedAnnual report
「To reflect actual market prices, official drug prices are normally revised in April once every 2 years, and official prices for most products are reduced. In recent years, partial revisions have also been conducted in April of the intervening years, resulting in annual drug price revisions. In addition, products whose markets have expanded by at least a certain scale due to added indications or other factors are revised 4 times a year.」
Regarding drug price revisions, it describes the possibility of annual partial revisions and 4 revisions a year in addition to the regular biennial revisions, indicating an increase in the frequency and potential impact of revisions. - FY2024-Q3RestatedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, the healthcare cost savings from the April 2023 drug price revision amounted to approximately ¥310 billion. Discussions toward fundamental reform of policies and systems related to people's lives and health, including social security and drug pricing, are expected to intensify, and policies to contain pharmaceutical spending are expected to continue.」
It reconfirms the approximately ¥310 billion in healthcare cost savings from the April 2023 drug price revision and the outlook for continued policies to contain pharmaceutical spending. - FY2024-Q2RestatedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, the healthcare cost savings from the April 2023 drug price revision amounted to approximately ¥310 billion. Discussions toward fundamental reform of policies and systems related to people's lives and health, including social security and drug pricing, are expected to intensify, and policies to contain pharmaceutical spending are expected to continue.」
It reconfirms the approximately ¥310 billion in healthcare cost savings from the April 2023 drug price revision and the outlook for continued policies to contain pharmaceutical spending. - FY2024-Q1MaterialisedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, the healthcare cost savings from the April 2023 drug price revision amounted to approximately ¥310 billion. Discussions toward fundamental reform of policies and systems related to people's lives and health, including social security and drug pricing, are expected to intensify, and policies to contain pharmaceutical spending are expected to continue.」
It states that the healthcare cost savings from the April 2023 drug price revision amounted to approximately ¥310 billion and reconfirms that policies to contain pharmaceutical spending will continue. - FY2023-Q1MaterialisedAnnual report
「Although the drug price revision had a negative impact of 6.69% on a pharmaceutical spending basis,」
It states that the 6.69% negative impact of the drug price revision actually arose in the first quarter and that negative accounting treatment related to the old and new wholesale prices of inventory held at the end of the previous fiscal year further weighed on profit progress. - FY2022WorsenedAnnual report
「Prescription drugs underwent 4 price revisions over approximately two and a half years, in October 2019, April 2020, April 2021 and April 2022. Annual drug price revisions are planned going forward, and policies to contain pharmaceutical spending are expected to continue.」
It emphasizes the frequency and continuing nature of drug price controls, noting that 4 drug price revisions were conducted over approximately two and a half years and that annual revisions are planned going forward. - FY2022-Q3RestatedAnnual report
「In the April 2021 mid-year revision, the scope greatly exceeded initial expectations, resulting in a negative revision of approximately ¥430 billion on a pharmaceutical spending basis in the fiscal 2021 budget.」
It reconfirms that the April 2021 mid-year drug price revision greatly exceeded initial expectations, resulting in a negative revision of approximately ¥430 billion. - FY2022-Q2RestatedAnnual report
「In the April 2021 mid-year revision, the scope greatly exceeded initial expectations, resulting in a negative revision of approximately ¥430 billion on a pharmaceutical spending basis in the fiscal 2021 budget.」
It reconfirms that the April 2021 mid-year drug price revision greatly exceeded initial expectations, resulting in a negative revision of approximately ¥430 billion. - FY2022-Q1WorsenedAnnual report
「In the April 2021 mid-year revision, the scope greatly exceeded initial expectations, resulting in a negative revision of approximately ¥430 billion on a pharmaceutical spending basis in the fiscal 2021 budget.」
It states that the April 2021 mid-year drug price revision greatly exceeded initial expectations, resulting in a negative revision of approximately ¥430 billion on a pharmaceutical spending basis. - FY2021MaterialisedAnnual report
「Results for the consolidated fiscal year were the most challenging since the fiscal year ended March 2011, when the Great East Japan Earthquake occurred, due to lower demand for pharmaceuticals resulting from the spread of COVID-19, lower revenue resulting from successive drug price revisions, and lower gross profit resulting from intensifying market competition, among other factors.」
It states that drug price revision risk appeared in full-year results as declines in revenue and gross profit, together with lower demand due to COVID-19 and intensifying market competition. - FY2021-Q3MaterialisedAnnual report
「In addition to the impact of price reductions from the October 2019 and April 2020 drug price revisions and price competition with industry peers, sales declined substantially.」
It states that the reductions from the October 2019 and April 2020 drug price revisions, together with price competition with industry peers, appeared in results for the first nine months as a substantial decline in sales. - FY2021-Q2RestatedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, official drug prices were reduced by an average of 4.38% in the April 2020 drug price revision as part of the government's healthcare cost-containment measures. Policies to contain pharmaceutical spending are expected to continue.」
It reconfirms the average 4.38% reduction in official drug prices in April 2020 and the expectation that policies to contain pharmaceutical spending will continue. - FY2021-Q1MaterialisedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, official drug prices were reduced by an average of 4.38% in the April 2020 drug price revision as part of the government's healthcare cost-containment measures. Policies to contain pharmaceutical spending are expected to continue.」
It newly states as an implemented fact that official drug prices were reduced by an average of 4.38% in April 2020 and that the impact of policies to contain pharmaceutical spending is continuing. - FY2020MaterialisedAnnual report
「Official drug prices for prescription drugs were reduced by an average of 7.48% in the April 2018 drug price revision. In addition, the October 2019 revision reduced official drug prices by an average of 2.40%, including a 1.95% increase to reflect the consumption tax.」
It states that the average 2.40% reduction in official drug prices in October 2019 was newly implemented and that the impact of policies to contain pharmaceutical spending is continuing. - FY2020-Q3MaterialisedAnnual report
「In addition, the October 2019 drug price revision reduced official drug prices by an average of 2.40%, including a 1.95% increase to reflect the consumption tax. Policies to contain pharmaceutical spending are expected to continue.」
It states that the October 2019 drug price revision implemented an average 2.40% reduction in official drug prices, presenting the impact of policies to contain pharmaceutical spending as a newly realized fact. - FY2020-Q2RestatedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, official drug prices were reduced by an average of 7.48% in the April 2018 drug price revision as part of the government's healthcare cost-containment measures. Policies to contain pharmaceutical spending are expected to continue.」
It reconfirms the average 7.48% reduction in official drug prices in April 2018 and the expectation that policies to contain pharmaceutical spending will continue. - FY2020-Q1RestatedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, official drug prices were reduced by an average of 7.48% in the April 2018 drug price revision as part of the government's healthcare cost-containment measures. Policies to contain pharmaceutical spending are expected to continue.」
It reconfirms the average 7.48% reduction in official drug prices in April 2018 and the expectation that policies to contain pharmaceutical spending will continue. - FY2019WorsenedAnnual report
「Policies aimed at containing social security spending, particularly on healthcare and long-term care, and operating the systems efficiently are expected to continue. Although the Group's core business, prescription drug wholesaling, has resilient demand, it is entering an increasingly difficult environment, with the market as a whole expected potentially to contract.」
In addition to the continuation of policies to contain pharmaceutical spending, it mentions the possibility that the prescription drug wholesaling market as a whole could contract, underscoring the challenging business environment. - FY2019-Q3RestatedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, official drug prices were reduced by an average of 7.48% in the April 2018 drug price revision as part of the government's healthcare cost-containment measures. Policies to contain pharmaceutical spending are expected to continue.」
It reconfirms the average 7.48% reduction in official drug prices in April 2018 and the expectation that policies to contain pharmaceutical spending will continue. - FY2019-Q2RestatedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, official drug prices were reduced by an average of 7.48% in the April 2018 drug price revision as part of the government's healthcare cost-containment measures. Policies to contain pharmaceutical spending are expected to continue.」
It reconfirms the average 7.48% reduction in official drug prices in April 2018 and the expectation that policies to contain pharmaceutical spending will continue. - FY2018MaterialisedAnnual report
「Official drug prices for prescription drugs were reduced by an average of 7.48% in the April 2018 drug price revision. Policies to contain pharmaceutical spending are expected to continue.」
It states that the average 7.48% reduction in official drug prices was implemented in the April 2018 revision and that policies to contain pharmaceutical spending will continue. - FY2018-Q3RestatedAnnual report
「In the pharmaceutical wholesaling industry, the Group's principal business, official drug prices were reduced by 7.8% in the April 2016 drug price revision as part of the government's healthcare cost-containment measures. Policies to contain pharmaceutical spending are expected to continue.」
It reiterates that the 7.8% reduction in official drug prices has been implemented and that policies to contain pharmaceutical spending will continue. - FY2018-Q2MaterialisedAnnual report
「During the second quarter cumulative consolidated period, the prescription drug market contracted in the Group's principal business, pharmaceutical wholesaling, due to lower sales of hepatitis C drugs and the impact of the emergency price revision for the anticancer drug Opdivo, among other factors.」
It states that the contraction in the prescription drug market resulting from drug price revisions and other factors actually affected results for the first six months. - FY2018-Q1MaterialisedAnnual report
「During the first quarter cumulative consolidated period, the prescription drug market contracted in the Group's principal business, pharmaceutical wholesaling, due to lower sales of hepatitis C drugs and the impact of the emergency price revision for the anticancer drug Opdivo, among other factors.」
It states that the impact of the market contraction from drug price revisions, including the emergency price revision for Opdivo, actually appeared in first-quarter results. - FY2017RestatedAnnual report
「The April 2016 drug price revision reduced official drug prices by 7.8%. Policies to contain pharmaceutical spending are expected to continue.」
It reiterates that the 7.8% reduction in official drug prices has been implemented and that policies to contain pharmaceutical spending will continue. - FY2017-Q2RestatedAnnual report
「Under the government's healthcare cost-containment measures, the April 2016 drug price revision resulted in a 7.8% reduction in official drug prices. Policies to curb pharmaceutical spending are expected to continue.」
The statement reiterates the 7.8% reduction in official drug prices and the view that policies to curb pharmaceutical spending will continue. - FY2017-Q1RestatedAnnual report
「Under the government's healthcare cost-containment measures, the April 2016 drug price revision resulted in a 7.8% reduction in official drug prices. Policies to curb pharmaceutical spending are expected to continue.」
The statement again records the 7.8% reduction in official drug prices and the view that policies to curb pharmaceutical spending will continue. “Quantified” and “materialized” reflect the fact that the drug price reduction has already been implemented. - FY2016First statedAnnual report
「The April 2016 drug price revision resulted in a 7.8% reduction in official drug prices. Policies to curb pharmaceutical spending are expected to continue.」
The statement indicates that lower drug prices and healthcare cost-containment policies may affect performance.